Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.700
+0.070 (4.29%)
At close: Apr 15, 2026, 4:00 PM EDT
1.710
+0.010 (0.59%)
After-hours: Apr 15, 2026, 7:49 PM EDT
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$19,129
Profits / Employee
-$1,479,871
Market Cap
116.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 31 | -2 | -6.06% | 30 | 1 |
| Dec 31, 2024 | 33 | 1 | 3.13% | 32 | 1 |
| Dec 31, 2023 | 32 | 6 | 23.08% | 31 | 1 |
| Dec 31, 2022 | 26 | 3 | 13.04% | 25 | 1 |
| Dec 31, 2021 | 23 | 11 | 91.67% | 22 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 142 |
| Seer, Inc. | 124 |
| Cibus | 118 |
| Pyxis Oncology | 56 |
| Equillium | 35 |
| Genelux | 26 |
| AN2 Therapeutics | 21 |
| ProMIS Neurosciences | 11 |
CRDF News
- 6 days ago - Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - GlobeNewsWire
- 26 days ago - Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 27 days ago - Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 2 months ago - Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - GlobeNewsWire